此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Basket Study of CTA313 in Participants With Active Autoimmune Diseases (ALLNEW)

2026年8月19日 更新者:Imviva Bio

A Single-Arm, Open-Label, Multi-Center, Phase Ib Basket Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTA313 in Participants With Active Autoimmune Diseases

The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.

Participants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate.

Participants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313.

Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.

研究概览

研究类型

介入性

注册 (估计的)

81

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Key Inclusion Criteria:

  • Male or female, ≥ 18 and ≤ 75 years of age
  • Adequate organ function
  • Diagnosed with one of the following in addition to meeting disease-specific criteria:

    1. Refractory Systemic Lupus Erythematosus (SLE) defined as an inadequate response to at least two immunomodulatory agents and one biologic agent
    2. Primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
    3. Autoimmune Encephalitis (AIE)

Key Exclusion Criteria:

  • Coexisting autoimmune diseases that could interfere with the attribution of disease activity or pose an increased safety risk
  • Participants with the following cardiac conditions are excluded:

    1. History of heart failure New York Heart Association (NYHA) class III or IV;
    2. History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.
  • History of severe central nervous system (CNS) disorders that could compromise the participant's ability to comply with protocol requirements or interfere with the accuracy of study assessments
  • Current or prior malignancy unless the malignancy was treated with curative intent and the subject has no known active malignant disease present for ≥ 5 years before enrollment
  • Primary immune deficiency
  • Presence of uncontrolled infections
  • History of untreated hepatitis C virus, or syphilis
  • History of HIV infection, or active or latent hepatitis B virus (HBV) infection.
  • Evidence of active Epstein-Barr virus (EBV), cytomegalovirus (CMV) or tuberculosis (TB)
  • History of prior CAR-T cell therapy or any other genetically modified immune cell therapy
  • Having received live/attenuated vaccine within 4 weeks prior to enrollment
  • Participants with a history of hypersensitivity to tacrolimus
  • Those who have participated in other interventional clinical trials within 30 days before enrollment
  • Participants who meet disease-specific exclusionary criteria as specified

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CTA313 UCAR T Cell Infusion
CAR T cells

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety Profile
大体时间:24 months
Incidence and severity of adverse events including dose limiting toxicities
24 months
RP2D Determination
大体时间:24 months
Determine the RP2D based on safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy.
24 months

次要结果测量

结果测量
措施说明
大体时间
Preliminary Efficacy - SLE
大体时间:24 months
Proportion of participants achieving DORIS and LLDAS
24 months
Preliminary Efficacy - pMS
大体时间:24 months
Proportion of patients without disability progression as defined by change in EDSS
24 months
Preliminary Efficacy - AIE
大体时间:24 months
Proportion of patients achieving functional improvement and/or response by modified Rankin Scale (mRS)
24 months
Characterize the cPK profile of CTA313
大体时间:24 months
Evaluate CTA313 cellular pharmacokinetic (PK) by measuring expansion, distribution and persistence
24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年9月1日

研究注册日期

首次提交

2026年8月17日

首先提交符合 QC 标准的

2026年8月19日

首次发布 (实际的)

2026年8月24日

研究记录更新

最后更新发布 (实际的)

2026年8月24日

上次提交的符合 QC 标准的更新

2026年8月19日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅